
ACT Brief: Zip Code Trial Access, Smaller Biotech APAC Perceptions, and Pimjetmi Tumor Approval
13.11.2026
0:00
1:30
In today’s ACT Brief, we examine how ZIP code shapes trial availability and enrollment, why smaller biotechs hold outdated views of APAC sites, and how FDA approved Pimjetmi for symptomatic tenosynovial giant cell tumor.
Flere episoder fra "Applied Clinical Trials"



Gå ikke glip af nogen episoder af “Applied Clinical Trials” - abonnér på podcasten med gratisapp GetPodcast.








